Samsung Bioepis research suggests lower immunogenicity for its Enbrel biosimilar

23 January 2018

A research note from Samsung Bioepis, accepted for publication in the British Journal of Dermatology, suggests the firm’s etanercept biosimilar may be less immunogenic than the reference product Enbrel, produced by Amgen (Nasdaq: AMGN).

The privately-held biosimilars powerhouse, founded in 2012, received marketing approval for the product in Europe in early 2016, where it is sold as Benepali. Elsewhere it is marketed as Brenzys.

The letter from trial investigators finds that injection site reactions such as rashes and itching occurred in 3.7% of those who received the biosimilar, and 17.5% of Enbrel patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK